# Trade Mark Journal No.2026/003 16 January 2026

## WO0000001893076 (1,5,42)

Office of origin: United States of America

Date of International Registration:28 August 2025
Date of designation in the UK: 28 August 2025

International priority date claimed: 11 July 2025 (United States of America) (99279029)

Class 1
  Chemical compounds in the nature of nucleotides for scientific and research use; chemical compounds in the nature of nucleotides for use in the manufacture of pharmaceuticals.
Class 5
  Pharmaceutical preparations, namely, RNA-based therapeutics for use in the treatment of complement-mediated, immune-related, genetic, cardiovascular, central nervous system, and metabolic diseases, conditions, and disorders, and cancer.
Class 42
  Development of pharmaceutical preparations and medicines; pharmaceutical products development; pharmaceutical research and development; scientific research and development in the field of RNA-based therapeutics; design and testing of RNA agents; bioinformatics and genomic data analysis for therapeutic development.

ADARX PHARMACEUTICALS, INC.

Representative: Christina M. Licursi Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston MA 02210-2206, UNITED STATES OF AMERICA